We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richter's Transformation.
- Authors
Ortiz-Maldonado, Valentín; Frigola, Gerard; Español-Rego, Marta; Balagué, Olga; Martínez-Cibrián, Nuria; Magnano, Laura; Giné, Eva; Pascal, Mariona; Correa, Juan G.; Martínez-Roca, Alexandra; Cid, Joan; Lozano, Miquel; Villamor, Neus; Benítez-Ribas, Daniel; Esteve, Jordi; López-Guillermo, Armando; Campo, Elías; Urbano-Ispizua, Álvaro; Juan, Manel; Delgado, Julio
- Abstract
CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter's transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high-risk CLL or RT.
- Subjects
RICHTER syndrome; CHRONIC lymphocytic leukemia; CYTOKINE release syndrome; PATIENTS' attitudes
- Publication
Frontiers in Oncology, 2022, Vol 12, p1
- ISSN
2234-943X
- Publication type
Article
- DOI
10.3389/fonc.2022.828471